ezetimibe has been researched along with Complications of Diabetes Mellitus in 22 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 12 (54.55) | 29.6817 |
| 2010's | 10 (45.45) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ahmad, S; Alvi, SS; Chaturvedi, CP; Iqbal, D; Khan, MS; Nabi, R; Shah, A | 1 |
| Jaffa, FM; Johnson, E; Kalyani, RR; Shubrook, JH; Skolnik, N | 1 |
| Choby, B | 1 |
| Abe, M; Fukuda, N; Haketa, A; Hatanaka, Y; Kobayashi, H; Nakamura, Y; Soma, M; Tanaka, S; Tsunemi, A; Ueno, T | 1 |
| Farrell, GC; Gan, LT; Haigh, WG; Ioannou, G; Larter, CZ; Teoh, NC; Van Rooyen, DM; Yeh, MM | 1 |
| Hamai, J; Kamiko, K; Kawasaki, S; Kondo, Y; Nezu, U; Shigematsu, E; Takahashi, M; Takano, T; Terauchi, Y; Yamada, M; Yamakawa, T; Yamazaki, S; Yoshii, T | 1 |
| Coffman, CJ; Crowley, MJ; Edelman, D; Fredrickson, SK; Jeffreys, AS; Melnyk, SD; Ostroff, JL | 1 |
| Kevelaitiene, S; Slapikas, R | 1 |
| Bybee, KA; Lavie, CJ; O'Keefe, JH | 1 |
| Elsais, A; Kerty, E; Lund, C | 1 |
| Fleg, JL; Galloway, JM; Henderson, JA; Howard, BV; Howard, WJ; Mete, M; Ratner, RE; Roman, MJ; Silverman, A; Stylianou, M; Umans, JG; Weir, MR; Wilson, C | 1 |
| Stein, EA | 1 |
| Abel, T; Dinya, E; Fehér, J; Gamal Eldin, M; Kovács, A | 1 |
| Cheng, SJ; Ma, Q; Xu, FX; Yan, HB | 1 |
| Arca, M; Budal, S; Degli Esposti, E; Degli Esposti, L; Sangiorgi, D; Vigna, GB | 1 |
| Almquist, T; Farndale, RW; Hjemdahl, P; Jacobson, SH; Lins, PE | 1 |
| Gu, P; Jiang, S; Lu, B; Shao, J; Wang, J; Zhong, Y | 1 |
| Busch, RS; Kane, MP; Stroup, JS | 1 |
| SoRelle, R | 1 |
| Gumbiner, B; Lee, M; Maccubbin, D; Masana, L; Shah, A; Simons, L; Tonkon, M | 1 |
| Patel, J | 1 |
3 review(s) available for ezetimibe and Complications of Diabetes Mellitus
| Article | Year |
|---|---|
Diabetes Update: Prevention and Management of Diabetes Complications.
Topics: Anticholesteremic Agents; Antihypertensive Agents; Cardiovascular Diseases; Depression; Diabetes Complications; Diabetic Nephropathies; Diabetic Neuropathies; Diabetic Retinopathy; Dyslipidemias; Ezetimibe; Gastroparesis; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension | 2017 |
[A new approach to the treatment of dyslipidemia].
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Diabetes Complications; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Middle Aged; Practice Guidelines as Topic; Prognosis; Pyrroles; Risk Factors | 2008 |
Dyslipidaemia in diabetes.
Topics: Azetidines; Bezafibrate; Diabetes Complications; Diabetic Angiopathies; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Fish Oils; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Niacin | 2006 |
5 trial(s) available for ezetimibe and Complications of Diabetes Mellitus
| Article | Year |
|---|---|
Can group medical clinics improve lipid management in diabetes?
Topics: Adult; Aged; Ambulatory Care Facilities; Anticholesteremic Agents; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Diabetes Complications; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertension; Male; Middle Aged; Treatment Outcome; Veterans | 2014 |
Effect of statins alone versus statins plus ezetimibe on carotid atherosclerosis in type 2 diabetes: the SANDS (Stop Atherosclerosis in Native Diabetics Study) trial.
Topics: Anticholesteremic Agents; Azetidines; Biomarkers; Carotid Artery Diseases; Carotid Artery, Common; Cholesterol, LDL; Diabetes Complications; Diabetes Mellitus, Type 2; Disease Progression; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Linear Models; Male; Middle Aged; Prospective Studies; Severity of Illness Index; Tunica Intima; Tunica Media | 2008 |
[Efficacy and safety of ezetimibe/simvastatin combination therapy in patients with type 2 diabetes and nonalcoholic fatty liver disease].
Topics: Aged; Alanine Transaminase; Anticholesteremic Agents; Aspartate Aminotransferases; Azetidines; Body Mass Index; Cholesterol, HDL; Cholesterol, LDL; Diabetes Complications; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Ezetimibe; Fatty Liver; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Simvastatin; Time Factors; Treatment Outcome; Waist Circumference | 2009 |
Effects of lipid-lowering treatment on platelet reactivity and platelet-leukocyte aggregation in diabetic patients without and with chronic kidney disease: a randomized trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Azetidines; Blood Platelets; Cross-Over Studies; Diabetes Complications; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Double-Blind Method; Ezetimibe; Female; Flow Cytometry; Follow-Up Studies; Glomerular Filtration Rate; Humans; Kidney Failure, Chronic; Leukocytes; Lipids; Male; Middle Aged; Platelet Activation; Platelet Aggregation; Prognosis; Risk Factors; Simvastatin; Young Adult | 2012 |
Effects of ezetimibe added to on-going statin therapy on the lipid profile of hypercholesterolemic patients with diabetes mellitus or metabolic syndrome.
Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Diabetes Complications; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Male; Metabolic Syndrome; Middle Aged | 2004 |
14 other study(ies) available for ezetimibe and Complications of Diabetes Mellitus
| Article | Year |
|---|---|
Modulatory role of HMG-CoA reductase inhibitors and ezetimibe on LDL-AGEs-induced ROS generation and RAGE-associated signalling in HEK-293 Cells.
Topics: Anticholesteremic Agents; Apoptosis; Diabetes Complications; Ezetimibe; Glycation End Products, Advanced; HEK293 Cells; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, LDL; NF-kappa B; Oxidative Stress; Reactive Oxygen Species; Receptor for Advanced Glycation End Products | 2019 |
Reducing CV risk in diabetes: An ADA update.
Topics: Antihypertensive Agents; Aspirin; Benzhydryl Compounds; Cardiovascular Diseases; Contraindications; Creatinine; Diabetes Complications; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Drug Chronotherapy; Ezetimibe; Fenofibrate; Glucosides; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertension; Hypoglycemic Agents; Hypolipidemic Agents; Life Style; Liraglutide; Metformin; Niacin; PCSK9 Inhibitors; Platelet Aggregation Inhibitors; Risk Reduction Behavior; Thiazolidinediones | 2017 |
Lipoprotein Lipase Deficiency Arising in Type V Dyslipidemia.
Topics: Adult; Age of Onset; Bezafibrate; Diabetes Complications; Ezetimibe; Genetic Variation; Heterozygote; Humans; Hyperlipoproteinemia Type I; Hypertriglyceridemia; Hypolipidemic Agents; Insulin Resistance; Lipoprotein Lipase; Male | 2019 |
Pharmacological cholesterol lowering reverses fibrotic NASH in obese, diabetic mice with metabolic syndrome.
Topics: Adiponectin; Animals; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol; Diabetes Complications; Drug Therapy, Combination; Ezetimibe; Fatty Liver; Female; Heptanoic Acids; Insulin; Liver; MAP Kinase Signaling System; Metabolic Syndrome; Mice; Mice, Mutant Strains; Mice, Obese; Non-alcoholic Fatty Liver Disease; Pyrroles | 2013 |
Second-line treatments for dyslipidemia in patients at risk of cardiovascular disease.
Topics: Aged; Azetidines; Cardiovascular Diseases; Cholesterol, LDL; Cohort Studies; Diabetes Complications; Dose-Response Relationship, Drug; Drug Monitoring; Drug Resistance; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Hospitals, Teaching; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Japan; Male; Middle Aged; Retrospective Studies; Risk Factors | 2014 |
Intensive lipid intervention in the post-ENHANCE era.
Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; Coronary Disease; Diabetes Complications; Disease Progression; Drug Therapy, Combination; Ezetimibe; Fluorobenzenes; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Kidney Failure, Chronic; Practice Guidelines as Topic; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2008 |
Ptosis, diplopia and statins: an association?
Topics: Adult; Atorvastatin; Autoantibodies; Autoimmune Diseases of the Nervous System; Azetidines; Blepharoptosis; Diabetes Complications; Diagnostic Errors; Diplopia; Eyelid Diseases; Ezetimibe; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Myasthenia Gravis; Myocardial Infarction; Pain; Pravastatin; Pyrroles; Receptors, Cholinergic; Recurrence; Strabismus | 2008 |
Additional lipid lowering trials using surrogate measurements of atherosclerosis by carotid intima-media thickness: more clarity or confusion?
Topics: Anticholesteremic Agents; Azetidines; Biomarkers; Carotid Arteries; Carotid Artery Diseases; Cholesterol, LDL; Diabetes Complications; Diabetes Mellitus, Type 2; Disease Progression; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Tunica Intima; Tunica Media | 2008 |
[Effectiveness of ezetimibe in improving lipid goal attainment in patients with coronary heart diseases treated with statin].
Topics: Alanine Transaminase; Anticholesteremic Agents; Aspartate Aminotransferases; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Creatine Kinase; Diabetes Complications; Drug Therapy, Combination; Ezetimibe; Humans; Hypercholesterolemia; Treatment Outcome; Triglycerides | 2009 |
[Achievement of therapeutic target in subjects on statin treatment in clinical practice. Results of the STAR (Statins Target Assessment in Real practice) study].
Topics: Aged; Algorithms; Azetidines; Biomarkers; Cardiovascular Diseases; Cerebrovascular Disorders; Cholesterol, LDL; Cohort Studies; Diabetes Complications; Diabetes Mellitus; Ezetimibe; Female; Fluorobenzenes; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Italy; Lovastatin; Male; Medication Adherence; Middle Aged; Pravastatin; Pyrimidines; Retrospective Studies; Risk Assessment; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2011 |
Effect of ezetimibe on insulin secretion in db/db diabetic mice.
Topics: Animals; Anticholesteremic Agents; Azetidines; Diabetes Complications; Diabetes Mellitus, Type 2; Ezetimibe; Glucose Intolerance; Hypercholesterolemia; Hypoglycemia; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin Secretion; Insulin-Secreting Cells; Islets of Langerhans; Kinetics; Male; Mice; Mice, Congenic; Mice, Mutant Strains; Random Allocation; Specific Pathogen-Free Organisms | 2012 |
The antilipidemic effects of ezetimibe in patients with diabetes.
Topics: Anticholesteremic Agents; Azetidines; Diabetes Complications; Ezetimibe; Humans; Hyperlipidemias | 2003 |
[Even at LDL cholesterol 100mg/dl. "Every coronary disease patient has to receive a statin"].
Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Diabetes Complications; Drug Therapy, Combination; Ezetimibe; Humans; Primary Prevention; Risk Factors; Simvastatin | 2003 |
Stenosis and the drug-eluting stent.
Topics: Angiotensin-Converting Enzyme Inhibitors; Anticholesteremic Agents; Azetidines; Cardiology; Coronary Restenosis; Diabetes Complications; Ezetimibe; Humans; Hypercholesterolemia; Myocardial Infarction; Myocardial Ischemia; Perindopril; Radionuclide Imaging; Randomized Controlled Trials as Topic; Stents | 2004 |